A study has shown a new drug — originally developed to tackle the scarring of organ tissue — could help to significantly improve the success rate of cancer immunotherapy treatment.
A study has shown a new drug — originally developed to tackle the scarring of organ tissue — could help to significantly improve the success rate of cancer immunotherapy treatment.